Repligen Corporation (RGEN)
| Market Cap | 6.62B |
| Revenue (ttm) | 738.26M |
| Net Income (ttm) | 48.89M |
| Shares Out | 56.40M |
| EPS (ttm) | 0.86 |
| PE Ratio | 136.55 |
| Forward PE | 59.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 731,962 |
| Open | 118.28 |
| Previous Close | 118.29 |
| Day's Range | 114.85 - 118.79 |
| 52-Week Range | 109.50 - 175.77 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 167.67 (+42.78%) |
| Earnings Date | May 5, 2026 |
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $167.67, which is an increase of 42.78% from the latest price.
News
Repligen to Report First Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its ...
Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management emphasized a broad, innovative product portfolio and strong customer engagement, driving above-market growth and margin expansion. Investments in talent, analytics, and digital solutions position the company for multi-year growth, with optimism for industry tailwinds and continued operational improvements.
Repligen Transcript: Leerink Global Healthcare Conference 2026
2026 guidance targets 9%-13% organic growth, driven by a strong order pipeline and capital equipment innovation, while managing gene therapy headwinds and macroeconomic factors. Margin expansion remains a priority, with strategic investments in Asia and technology expected to yield long-term benefits.
Repligen Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year growth, exceeding guidance with robust performance across all segments and geographies. 2026 outlook calls for 9%–13% organic growth, margin expansion, and continued investment in innovation and M&A, while monitoring macro and policy risks.
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET
Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference
Innovation and diversification drive strong growth, with a broadening product portfolio and expanding global presence. Margin expansion and operational leverage are key priorities, supported by investments in R&D, AI, and commercial infrastructure. Significant opportunities exist in reshoring and new modalities, with expectations for above-market growth and margin improvement through 2030.
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected...
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new hi...
Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference
Q3 saw 18% organic growth across all franchises, with strong performance in proteins, analytics, and ATF hardware. The outlook remains positive, targeting market outperformance by 500 basis points, despite headwinds from a major gene therapy customer. Margin expansion and onshoring opportunities are expected to drive long-term growth.
Repligen Corporation to Present at Evercore Healthcare Conference
WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participat...
Repligen Transcript: Wolfe Research Healthcare Conference 2025
Q3 saw 18% organic growth, led by analytics and ATF hardware, with strong momentum in equipment and emerging biotech. Policy shifts and reshoring are expected to drive future orders, while ongoing investments and bolt-on M&A support a plan to double revenue in five years.
Repligen Transcript: Jefferies London Healthcare Conference 2025
Strong organic growth is driven by innovation, clinical focus, and strategic expansion in Asia. Filtration and protein businesses are expanding through new technologies and partnerships, while new modalities and margin improvements support a positive five-year outlook.
Repligen Transcript: Stifel 2025 Healthcare Conference
Strong organic growth was driven by diverse product performance, especially in analytics and protein, with strategic investments in talent and innovation. Filtration and hardware segments remain robust, while new modalities and onshoring are set to fuel future expansion. China and clinical exposure offer additional growth tailwinds.
Repligen Transcript: UBS Global Healthcare Conference 2025
Strong organic growth and margin expansion were driven by broad portfolio strength, ATF systems, and analytics upgrades. Strategic focus remains on new modalities, biosimilars, and in-house resin development, with significant China and onshoring opportunities expected by 2027.
Repligen Earnings Call Transcript: Q3 2025
Q3 2025 saw 18% organic growth, double-digit gains across all franchises, and strong global performance. Revenue and margin guidance for 2025 were raised, with robust cash flow and continued strategic investments supporting future growth.
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...
Repligen to Report Third Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET
Repligen Transcript: Bank of America Global Healthcare Conference 2025
The session highlighted strong growth driven by innovation, a diversified product and customer base, and disciplined M&A. Recovery in biopharma and CDMO segments, expansion in Asia, and continued investment in new modalities and technology position the company for above-market growth. Margin expansion and operational efficiency remain key priorities.
Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Strong organic growth and order momentum led to raised guidance, with innovation in hardware, analytics, and consumables driving gains. China is poised for rapid biopharma expansion, requiring local strategies. Margin improvement and portfolio growth are expected, with M&A as a secondary focus.
Repligen Corporation to Present at Upcoming September Conferences
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending ...
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have...